Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Health and Human Services Food and Drug Administration [Docket No. FDA-2018-N-2194]
 AGENCY: Food and Drug Administration, HHS.
 ACTION: Notice.
 SUMMARY: The Food and Drug Administration (FDA or Agency) is withdrawing approval of five new drug applications (NDAs) from multiple applicants. The holders of the applications notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.
 DATES: Approval is withdrawn as of July 23, 2018.
 FOR FURTHER INFORMATION CONTACT: Florine P. Purdie, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6248, Silver Spring, MD 20993-0002, 301-796-3601.


SUPPLEMENTARY INFORMATION: The holders of the applications listed in the table have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications under the process in § 314.150(c) (21 CFR 314.150(c)). The applicants have also, by their requests, waived their opportunity for a hearing. Withdrawal of approval of an application or abbreviated application under § 314.150(c) is without prejudice to refiling. Application No.
Drug
ApplicantNDA 020831
Foradil Aerolizer (formoterol fumarate) Powder, 0.012 milligram (mg)/inhalation
Novartis Pharmaceuticals Corp., One Health Pl., East Hanover, NJ 07936.NDA 022504
Axiron (testosterone) Transdermal Metered Solution, 30 mg/1.5 milliliter (mL) actuation
Eli Lilly and Co., Lilly Corporate Center, Indianapolis, IN 46285.NDA 050585
Rocephin (ceftriaxone sodium) for Injection, equivalent to (EQ) 10 gram (g) base/vial, EQ 250 mg base/vial (IV/IM), EQ 500 mg base/vial (IV/IM), EQ 1 g base/vial (IV/IM), EQ 2 g base/vial (IV/IM), EQ 500 mg base/vial, N/A; N/A, 1% (Rocephin kit), EQ 1 g base/vial, N/A; N/A, 1% (Rocephin kit)
Hoffmann-La Roche, Inc., c/o Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080.NDA 050624
Rocephin (ceftriaxone sodium) with Dextrose in Plastic Container Injection, EQ 10 mg base/mL, EQ 20 mg base/mL, and EQ 40 mg base/mL
Do.NDA 202763
Testosterone Gel, 25 mg/2.5 g packet, 50 mg/5 g packet
ANI Pharmaceuticals, Inc., 210 Main St. West, Baudette, MN 56623.
 
 
 Therefore, approval of the applications listed in the table, and all amendments and supplements thereto, is hereby withdrawn as of July 23, 2018. Introduction or delivery for introduction into interstate commerce of products without approved new drug applications violates section 301(a) and (d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331(a) and (d)). Drug products that are listed in the table that are in inventory on July 23, 2018 may continue to be dispensed until the inventories have been depleted or the drug products have reached their expiration dates or otherwise become violative, whichever occurs first. Dated: June 14, 2018. Leslie Kux, Associate Commissioner for Policy.


[FR Doc. 2018-13293 Filed 6-20-18; 8:45 am] BILLING CODE 4164-01-P